ABOS

-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS) at 18 months compared to placebo at either dose; key secondary endpoints, including CDR-SB, also did not achieve statistical significance -- -- Acumen to cease clinical development of sabirnetug, preserve cash and explore strategic options --

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript

Acumen Pharmaceuticals NASDAQ: ABOS said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer's disease.

NEWTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key poster presentations at the upcoming 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference taking place in Boston. The presentations focus on Acumen's Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) for the treatment of early AD, including preliminary baseline characteristics of study participants, study participant and partner experience, and treatment expectations and motivations. The conference will be held November 16-19, 2026, both in-person and online. “These presentations reflect Acumen's commitment to understanding the biology of early AD as well as the full experience, including the perspectives of patients and care partners living with it every day,” said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. “These important insights from our study collaborators and participants in ALTITUDE-AD help keep their needs at the center of our efforts to advance sabirnetug as a potential treatment of choice for AD.”

NEWTON, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report third quarter financial results on Monday, Oct. 26, 2026. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in the following upcoming investor conferences.